The Ledger
Every statement that passed quotation and attribution checks. Mix any filter with any other: certainty 1/5, debate potential 5/5, or both at once.
why aren't all 17 resolved? a statement only gets an assessment when the public record can support or contradict it. opinions and what-ifs never can, and 0 checkable ones are still open, waiting for their date. predictions held up or didn't; assertions are supported or contradicted. on every card: ▮▮▮▮▮ certainty · ▮▮▮▮▮ debate potential. speakers are clickable
Wickramasekara: 60% of Benchling customers' laboratory instruments are unconnected
“The last time we kind of ran one of these benchmarking exercises was that For our customers, 60% of their instruments are not connected.”
Wickramasekara: Vertical software markets are less competitive, risking loss of focus
“One thing actually that's probably worse about vertical companies is you, the markets are not as competitive as horizontal companies, and so you can get a little unfocused at times”
Wickramasekara: Biologics and advanced modalities now dominate biopharma pipelines
“Biologics, advanced modalities are now majority of the pipeline. We actually have approved cell therapies, gene therapies. We're the first gene editing medicines approved.”
Wickramasekara: Pharma researchers do not lack tech literacy
“I think there's sometimes this, like, unfair caricature that people in pharma, like, don't know how to turn on a computer and that the industry just, like, doesn't believe in technology and so forth. I don't think belief in the technology is, like, lacking. I …”
Wickramasekara: Biological research software requires highly flexible data models
“The data and the technological needs of serving biology are very, very different. You have an incredibly complex multidimensional data model that's happening while the instrumentation lab is now, you know, vastly generating more, more data than ever, ever befo…”
Wickramasekara: Benchling has 800 employees and spends $100M annually on R&D
“We are, 800 people today. We, I think about 40% of our team works in R&D, probably spend a hundred million dollars a year on, on R&D.”
Wickramasekara: Bio AI models will 10x therapeutic molecule ideas
“I think these new bio AI models are gonna 10 X the number of really high quality ideas for therapeutic, therapeutic molecules.”
Wickramasekara: The life sciences industry is sleeping on in vivo data
“I think in vivo data is something people are sleeping on, actually.”
Wickramasekara: Benchling wouldn't exist if he knew it required enterprise sales
“If you had told me when I was 21 that I was signing up to do like enterprise sales to big pharma, I'd have been like, absolutely not. I'm not starting this company.”
Wickramasekara: Enterprise buyers evaluate multi-year trajectory over current capabilities
“Enterprises are not buying for the present moment. They are buying like Multi-year.”
Wickramasekara: Scaling Benchling to $1M ARR was 100x harder than scaling further
“Going from kind of zero to one was a hundred times harder than one to N.”
Wickramasekara: Benchling is well past $100M in annual recurring revenue
“Well past hundred, but still very hard.”
Wickramasekara: 100 deeply addicted users signal broader market demand
“If 10 people or a hundred people Were totally addicted to the software. Like that was a really good sign. Like, cause what are the chances that we found just the exact hundred people who would be completely addicted and there'd be no one else after that? So I …”
Benchling failed at enterprise sales until adding business-level data features
“And actually though, at first, like we really like struck out trying to sell anything to these companies. Like scientists have used Benchling in school. They liked it, but they weren't going to buy it. The business, like the value wasn't there. And that's when…”
Benchling sells professional services with every single customer deal
“And so we heavily employ services. We sell services with every deal we do.”